The numbers are staggering IF there are no
credible competitors appearing before and
after FDA approval.
We know of at least 2 probable competitors
already in Phase 3.
Can we just temper the bias confirmation
for one minute?
- Forums
- ASX - By Stock
- PAR
- iPPS and the not so Looney comparison
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
3.23%
!
45.0¢

iPPS and the not so Looney comparison, page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
45.0¢ |
Change
-0.015(3.23%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
47.0¢ | 47.5¢ | 43.0¢ | $162.8K | 357.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 55560 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 5665 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 30560 | 0.450 |
1 | 8166 | 0.440 |
2 | 15000 | 0.435 |
3 | 102031 | 0.430 |
4 | 161397 | 0.425 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 37781 | 3 |
0.475 | 40515 | 5 |
0.480 | 205598 | 5 |
0.485 | 23239 | 2 |
0.490 | 18000 | 2 |
Last trade - 10.19am 07/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online